These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28927101)

  • 1. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
    He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
    Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
    Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
    Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
    Huang ZL; Cao X; Luo RZ; Chen YF; Zhu LC; Wen Z
    Oncol Lett; 2016 Jan; 11(1):299-305. PubMed ID: 26870207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed Tomography Manifestations and Excision Cross-Complementation Group 1 Expression of Stage I Non-Small-Cell Lung Cancer and Their Correlation With Prognosis.
    Guan Y; You X; Li J; Xia T; Pan X; He J
    J Comput Assist Tomogr; 2016; 40(4):584-8. PubMed ID: 27434787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
    Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
    Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
    Rybárová S; Muri J; Hodorová I; Vecanová J; Benický M; Piovarči D; Janík P; Mihalik J; Mirossay L
    Klin Onkol; 2012; 25(5):370-4. PubMed ID: 23102199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
    Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
    Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
    Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.
    Breen D; Barlési F
    Eur J Cardiothorac Surg; 2008 May; 33(5):805-11. PubMed ID: 18342529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.